From the bench to the bedside: emerging new treatments in multiple myeloma.
about
A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma.Selinexor Overcomes Hypoxia-Induced Drug Resistance in Multiple Myeloma.Molecular chaperone GRP78 enhances aggresome delivery to autophagosomes to promote drug resistance in multiple myeloma.Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myelomaBone marrow microenvironment and the identification of new targets for myeloma therapy.Survival from multiple myeloma in England and Wales up to 2001.A CD138-independent strategy to detect minimal residual disease and circulating tumour cells in multiple myeloma.In pursuit of the allo-immune response in multiple myeloma: where do we go from here?Nuclear effects of ethanol-induced proteasome inhibition in liver cellsInsights into defibrotide: an updated review.Growth factors in tumor microenvironment.Kinase inhibitors as potential agents in the treatment of multiple myeloma.Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.Heat-shock protein 90 inhibitors as antitumor agents: a survey of the literature from 2005 to 2010.Nanoparticle delivery systems, general approaches, and their implementation in multiple myeloma.Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics.Selenium-containing histone deacetylase inhibitors for melanoma management.The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivoDefibrotide blunts the prothrombotic effect of thalidomide on endothelial cells.Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells.Potentiation of apoptosis by histone deacetylase inhibitors and doxorubicin combination: cytoplasmic cathepsin B as a mediator of apoptosis in multiple myeloma.Cytotoxicity on human cancer cells of ophidiacerebrosides isolated from the African starfish Narcissia canariensis.HDAC inhibition synergistically enhances alkylator-induced DNA damage responses and apoptosis in multiple myeloma cells.In vitro and in vivo rationale for the triple combination of panobinostat (LBH589) and dexamethasone with either bortezomib or lenalidomide in multiple myelomaPeroxisome proliferator-activated receptor gamma agonists potentiate the cytotoxic effect of valproic acid in multiple myeloma cells.Proteasome-associated deubiquitinases and cancer.Tris DBA palladium overcomes hypoxia-mediated drug resistance in multiple myeloma.153Sm: its use in multiple myeloma and report of a clinical experience
P2860
Q30498959-6E62418D-70BE-4C0F-805C-0E6DD7558ED5Q33410997-A884D3D5-C11D-441B-B205-629B94B4BD99Q33868512-F000696E-F24F-41AC-B6FD-69009D9D66F7Q35550181-386C9338-2F75-401A-B876-CC4B2CB1E747Q35915726-C32CCFBC-A8CD-40C7-897D-82DB76430671Q36162703-A30395EE-7EED-433E-9589-2DA76B1CFBC0Q36917738-3669F4BF-71A0-4BA7-9092-4F483054F2BFQ37032148-77F26D4B-0D3E-48FC-A1DF-B5D8E4BFC78AQ37349835-0D9FB43B-052F-4463-8AF0-A8E135FEDA14Q37416573-BD4376B2-EFDE-487B-A61D-B9AAEB08548CQ37489891-F56D5C8A-3194-427D-8074-110358B2172EQ37663172-CEBDD0BB-6829-4E25-B649-3AD9381C7EFCQ37697253-0048223F-ED27-4E53-9CEB-ADC31EAD1C68Q37813152-C3FB639D-3C07-4609-AE8C-65A8A834FAA0Q37891987-D672F4E6-4826-4BB8-97B8-BEC8D7822126Q39139112-7A990A32-5A60-47BB-88D7-D58A0D823243Q39234159-B8D7F216-3C9D-4AE3-B388-B650D0685704Q39336516-F8C38BC2-CE02-481F-819C-D7CEB4711A51Q39407246-E0C6E365-0EDE-4CC0-BAAE-839DE27B29EDQ39511703-4E138D99-61B9-4C18-9497-98198AA52598Q39527860-AC757C5E-928A-401F-8212-8CCBB90292CDQ39583526-07532B58-89AA-4143-9FC2-05036D7FDDC4Q39588314-A0ED3A96-E3E5-4582-80B8-C0ECF6A51D7BQ39706886-F1969BD9-AF41-49EE-BDE1-448AFE8997DEQ39768627-48D34D1C-C8BA-4D82-B7A0-275642439EB3Q43269070-18FB5276-7E6B-46A1-B49D-E634FC6CB0D1Q47161331-DBCC4F19-B00E-4B12-9248-4E6A55791E09Q48073647-609A295C-C10E-4649-9127-C297C889BCA2Q58449064-B128DEF8-6C5D-4A99-9DDE-93655D275F47
P2860
From the bench to the bedside: emerging new treatments in multiple myeloma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
From the bench to the bedside: emerging new treatments in multiple myeloma.
@en
From the bench to the bedside: emerging new treatments in multiple myeloma.
@nl
type
label
From the bench to the bedside: emerging new treatments in multiple myeloma.
@en
From the bench to the bedside: emerging new treatments in multiple myeloma.
@nl
prefLabel
From the bench to the bedside: emerging new treatments in multiple myeloma.
@en
From the bench to the bedside: emerging new treatments in multiple myeloma.
@nl
P2860
P1476
From the bench to the bedside: emerging new treatments in multiple myeloma.
@en
P2093
Constantine S Mitsiades
Patrick J Hayden
P2860
P304
P356
10.1016/J.BEHA.2007.09.008
P577
2007-12-01T00:00:00Z